TOKYO -- The Japanese health ministry's expert board on Monday postponed a decision on whether to approve Fujifilm Holdings' Avigan for coronavirus treatment, opting to examine more evidence to determine its efficacy.
Coronavirus
Japan health ministry delays decision on Avigan for coronavirus
Authorities seek additional data before greenlighting Fujifilm flu drug
Avigan, also known by its generic name favipiravir, was shown to accelerate recovery in COVID-19 patients with non-severe pneumonia in a clinical trial by Fujifilm Toyama Chemical. © Reuters
Read Next
Latest on Coronavirus
